PCM
IPXL

Price Capital Management’s Impax Laboratories, Inc. IPXL Stock Holding History

Price Capital Management’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-15,487
Closed -$726K – 266
2015
Q1 		$726K Buy
+15,487
New +$616K 0.45% 51

Other funds holding IPXL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PCM
Pennant Capital Management Summit, New Jersey $212M AUM 19.37% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AG
Aravt Global New York $11.3M AUM 3.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Price Capital Management's IPXL Position: Q2 2015 in Review

Price Capital Management sold out of Impax Laboratories, Inc. (IPXL) in Q2 2015, closing a stake of 15,487 shares — an estimated $726K sold.

Price Capital Management first reported a position in IPXL in Q1 2015 and held it in 1 quarter. The position peaked at $726K in Q1 2015. 197 funds tracked by Wall St. Rank hold IPXL as of Q2 2015.

  • Price Capital Management reported no remaining Impax Laboratories, Inc. position as of Q2 2015 after selling out during the quarter.
  • Price Capital Management sold 15,487 Impax Laboratories, Inc. shares in Q2 2015, an estimated $726K.
  • Price Capital Management first reported a position in Impax Laboratories, Inc. in Q1 2015 and held it in 1 quarter.
  • Price Capital Management's Impax Laboratories, Inc. position peaked at $726K in Q1 2015.
  • 197 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2015.

Based on Price Capital Management's 13F filing for Q2 2015.